Dr. Maya Guglin explains the pathophysiology of hypertrophic cardiomyopathy (HCM) and discusses what the results of the long-term extension study of EXPLORER-HCM could mean for patients with symptomatic obstructive HCM.
ReachMD
Be part of the knowledge.™Cardiac Myosin Inhibitor Sustainably Reduces LVOT Gradient in HCM
Choose a format
Media formats available:
Facebook Comments